UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status

British journal of cancer, 2011-11, Vol.105 (10), p.1533-1541

2011

Volltextzugriff (PDF)

Effects of 5-azacytidine and trichostatin A on dendritic cell maturation

Journal of biological regulators and homeostatic agents, 2011-10, Vol.25 (4), p.517-529

2011

Volltextzugriff (PDF)

297 Therapy of murine HPV 16-associated TC-1 tumours: suppression of T regulatory and myeloid derived suppressor cells

European journal of cancer supplements, 2010, Vol.8 (5), p.77-77

2010

Volltextzugriff (PDF)

Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines

Oncotarget, 2016-08, Vol.7 (34), p.54952-54964

2016

Volltextzugriff (PDF)

Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I molecules

Neoplasma, 2007, Vol.54 (4), p.326

2007

Volltextzugriff (PDF)

Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin

International journal of oncology, 2002-03, Vol.20 (3), p.643

2002

Volltextzugriff (PDF)

Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines

International journal of oncology, 2010-03, Vol.36 (3), p.545-551

2010

Volltextzugriff (PDF)

Interleukin‐2 gene therapy of surgical minimal residual tumour disease

International journal of cancer, 1998-03, Vol.76 (1), p.115-119

1998

Volltextzugriff (PDF)

HPV 16-associated tumours : IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy

International journal of oncology, 2009-01, Vol.34 (1), p.173-179

2009

Volltextzugriff (PDF)

HPV 16-ASSOCIATED TUMOURS: IN VITRO RESPONSES OF IMMUNE MICE AND MICE CURED WITH CHEMOTHERAPY AND SUBSEQUENT IL-12 IMMUNOTHERAPY

Anticancer research, 2008-10, Vol.28 (5C)

2008

Volltextzugriff (PDF)

IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours : Induction of immune responses, cytokine production and kinetics of immune cell subsets

International journal of oncology, 2008-02, Vol.32 (2), p.499-507

2008

Volltextzugriff (PDF)

CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours

International journal of oncology, 2007-05, Vol.30 (5), p.1247-1251

2007

Volltextzugriff (PDF)

A simple, optimized method for the determination of sulphide in whole blood by GC–MS as a marker of bowel fermentation processes

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2002-04, Vol.770 (1), p.255-259

2002

Volltextzugriff (PDF)

Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours

International journal of oncology, 2006, Vol.28 (1), p.253-259

2006

Volltextzugriff (PDF)

Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy

International journal of oncology, 2005-02, Vol.26 (2), p.521

2005

Volltextzugriff (PDF)

Loss of tumorigenicity of murine colon carcinoma MC38/0 cell line after transduction with a retroviral vector carrying murine IL-12 genes

Folia biologica, 2004, Vol.50 (1), p.7-14

2004

Volltextzugriff (PDF)

KINETICS AND FUNCTION OF PERITONEAL-EXUDATE CELLS DURING LOCAL IL-2 GENE-THERAPY OF CANCER

International journal of oncology, 1994-01

1994

Volltextzugriff (PDF)

Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF

International journal of oncology, 2004-01, Vol.24 (1), p.161

2004

Volltextzugriff (PDF)

Immunization with MHC class I-negative but not -positive HPV16-associated tumour cells inhibits growth of MHC class I-negative tumours

International journal of oncology, 2007-04, Vol.30 (4), p.1011-1017

2007

Volltextzugriff (PDF)

Interleukin-2 gene therapy of residual EL-4 leukaemia potentiates the effect of cyclophosphamide pretreatment

Journal of cancer research and clinical oncology, 1995, Vol.121 (1), p.39-43

1995

Volltextzugriff (PDF)

IFN-ALPHA THERAPY OF RENAL-CELL CARCINOMA - DEFECT OF LYMPHOCYTE SENSITIVITY TO MITOGENIC AND ACTIVATING CYTOKINE SIGNALS IN PATIENTS NOT-RESPONDING TO THERAPY

International journal of oncology, 1995-09

1995

Volltextzugriff (PDF)

Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A

Oncology reports, 2001-11, Vol.8 (6), p.1371

2001

Volltextzugriff (PDF)

Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16

Vaccine, 2003-02, Vol.21 (9), p.891-896

2003

Volltextzugriff (PDF)

HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines

International journal of oncology, 2004-10, Vol.25 (4), p.1165

2004

Volltextzugriff (PDF)

Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines

International journal of oncology, 2003-03, Vol.22 (3), p.691

2003

Volltextzugriff (PDF)

1 – 25 von 98

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(98)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(69)
Science & Technology
(69)
Animals
(68)
Mice
(63)
Oncology
(51)
Mice, Inbred C57bl
(29)
Male
(26)
Biochemistry & Molecular Biology
(24)
Humans
(24)
Biological And Medical Sciences
(23)
Cell Biology
(23)
Biology
(22)
Life Sciences & Biomedicine - Other Topics
(22)
Medical Sciences
(22)
Immunotherapy
(18)
Tumors
(15)
Interleukin-2 - Therapeutic Use
(14)
Neoplasm Transplantation
(14)
Cytotoxicity, Immunologic
(12)
Female
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status

Effects of 5-azacytidine and trichostatin A on dendritic cell maturation

297 Therapy of murine HPV 16-associated TC-1 tumours: suppression of T regulatory and myeloid derived suppressor cells

Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines

Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I molecules

Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin

Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines

Interleukin‐2 gene therapy of surgical minimal residual tumour disease

HPV 16-associated tumours : IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy

HPV 16-ASSOCIATED TUMOURS: IN VITRO RESPONSES OF IMMUNE MICE AND MICE CURED WITH CHEMOTHERAPY AND SUBSEQUENT IL-12 IMMUNOTHERAPY

IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours : Induction of immune responses, cytokine production and kinetics of immune cell subsets

CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours

A simple, optimized method for the determination of sulphide in whole blood by GC–MS as a marker of bowel fermentation processes

Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours

Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy

Loss of tumorigenicity of murine colon carcinoma MC38/0 cell line after transduction with a retroviral vector carrying murine IL-12 genes

KINETICS AND FUNCTION OF PERITONEAL-EXUDATE CELLS DURING LOCAL IL-2 GENE-THERAPY OF CANCER

Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF

Immunization with MHC class I-negative but not -positive HPV16-associated tumour cells inhibits growth of MHC class I-negative tumours

Interleukin-2 gene therapy of residual EL-4 leukaemia potentiates the effect of cyclophosphamide pretreatment

IFN-ALPHA THERAPY OF RENAL-CELL CARCINOMA - DEFECT OF LYMPHOCYTE SENSITIVITY TO MITOGENIC AND ACTIVATING CYTOKINE SIGNALS IN PATIENTS NOT-RESPONDING TO THERAPY

Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A

Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16

HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines

Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines

Suchergebnisse filtern